Yoshihiko Ooka

Yoshihiko Ooka

Auto-generated profile, based on publicly available information

Yoshihiko Ooka

Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2015 in Hepatology International
Verified
Journal Article
Open access
PDF file
TSTsunenobu Sato
Tsunenobu Sato
FKFukuo Kondo
Fukuo Kondo
MEMasaaki Ebara
Masaaki Ebara
NSNobuyuki Sugiura
Nobuyuki Sugiura
SOShinichiro Okabe
Shinichiro Okabe
OYOSAMU YOKOSUKA
OSAMU YOKOSUKA
Background and aims Some follow-up studies of large regenerative nodules (LRNs) and dysplastic nodules (DNs) were reported previously. However, the pre-malignant potentiality of LRNs has remained controversial up to now. No LRNs showed malignant transformation in our previous study. We aimed to evaluate the pre-malignant potentiality of LRNs and DNs with a greater number of cases and longer follow-up periods. Methods From 1982 to 2005, 1,500 consecutive nodular lesions up to 2 cm in diameter were subjected to US guided thin-needle biopsy in cirrhotic patients at Chiba University Hospital. Of these lesions, 68 LRNs in 60 cases and 20 DNs in 22 cases were followed up for more than 6 months without any anti-cancer therapy. The last US examination was in 2010. The total study period was 28 years. We analyzed the histological findings and the clinical data of all cases retrospectively. The outcome of the lesions was examined. Results The mean follow-up period was 38.9 (16–119) months in LRNs and 31.9 (6–101 months) in DNs. Rate of nodule enlargement was higher in DNs (8/24 nodules, 33 %) than LRNs (11/68 nodules, 16 %), (p = 0.0743, not significant). Rate of malignant transformation was also higher in DNs (10/24 nodules, 42 %) than LRNs (9/68 nodules, 13 %), (p = 0.0040, significant). The rate of disappearance in images was similar between LRNs and DNs. Conclusions We should recognize LRN as low risk pre-malignant lesions whereas DNs as high risk lesions.

1 June 2013 in Magnetic Resonance Imaging
Verified
Journal Article
Closed access
YOYoshihiko Ooka
Yoshihiko Ooka
FKFumihiko Kanai
Fumihiko Kanai
SOShinichiro Okabe
Shinichiro Okabe
TUTakuya Ueda
Takuya Ueda
RSRyota Shimofusa
Ryota Shimofusa
OYOSAMU YOKOSUKA
OSAMU YOKOSUKA

Verified
Journal Article
Open access
PDF file
Tatsuo KandaTatsuo Kanda
Tatsuo Kanda
SYShin Yasui
Shin Yasui
MNMasato Nakamura
Masato Nakamura
ESEiichiro Suzuki
Eiichiro Suzuki
MAMakoto Arai
Makoto Arai
OYOSAMU YOKOSUKA
OSAMU YOKOSUKA
The aim of this study was to characterize the treatment response and serious adverse events of ledipasvir plus sofosbuvir therapies in Japanese patients infected with hepatitis C virus (HCV) genotype 1 (GT1). This retrospective study analyzed 240 Japanese HCV GT1 patients treated for 12 weeks with 90 mg of ledipasvir plus 400 mg of sofosbuvir daily. Sustained virological response at 12 weeks post-treatment (SVR12) was achieved in 236 of 240 (98.3%) patients. Among treatment-naïve patients, SVR12 was achieved in 136 of 138 (98.6%) patients, and among treatment-experienced patients, SVR12 was achieved in 100 of 102 (98.0%) patients. In patients previously treated with peginterferon plus ribavirin with various HCV NS3/4A inhibitors, 100% SVR rates (25/25) were achieved. Two relapsers had HCV NS5A resistance-associated variants (RAVs), but no HCV NS5B-S282 was observed after they relapsed. We experienced two patients with cardiac events during treatment. In conclusion, combination of ledipasvir plus sofosbuvir for 12 weeks is a potential therapy for HCV GT1 patients. Caution is needed for HCV NS5A RAVs, which were selected by HCV NS5A inhibitors and cardiac adverse events.

5 October 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KKKazufumi Kobayashi
Kazufumi Kobayashi
SOSadahisa Ogasawara
Sadahisa Ogasawara
SMSusumu Maruta
Susumu Maruta
TOTOMOMI OKUBO
TOMOMI OKUBO
NINorio Itokawa
Norio Itokawa
NKNaoya Kato
Naoya Kato
Purpose: This study aimed to investigate the safety and efficacy of lenvatinib in real-world settings, including patients excluded from the REFLECT trial, a phase III trial that compared lenvatinib with sorafenib. Patients and Methods: This multicenter, nonrandomized, open-label prospective study was conducted at 10 medical facilities in Japan (jRCTs031190017). Eligible patients had advanced hepatocellular carcinoma (HCC) and were suitable for lenvatinib therapy. The study included patients with high tumor burden (with >50% intrahepatic tumor volume, main portal vein invasion, or bile duct invasion), Child-Pugh B status, and receiving lenvatinib as second-line therapy following atezolizumab plus bevacizumab. Results: From December 2019 to September 2021, 59 patients were analyzed (47 and 12 patients with Child-Pugh A and B, respectively). In patients with Child-Pugh A, the frequency of aspartate aminotransferase elevation was high (72.7%) in the high-burden group. No other significant ad verse events (AE) were observed even in second-line treatment. However, patients with Child-Pugh B had high incidence of grade ≥3 AE (100.0%) and high discontinuation rates caused by AE (33.3%) compared with patients with Child-Pugh A (80.9% and 17.0%, respectively). Median progression-free survival was 6.4 and 2.5 months and median overall survival was 19.7 and 4.1 months in Child-Pugh A and B, respectively. Lenvatinib plasma concentration was higher in patients with Child-Pugh B on days 8 and 15 and correlated with dose modifications and lower relative dose intensity. Conclusions: Lenvatinib is safe and effective for advanced HCC in patients with Child-Pugh A, even with high tumor burden. However, it carries a higher risk of AE and may not provide adequate efficacy for patients with Child-Pugh B status.

21 September 2018 in Hepatology International
Verified
Journal Article
Closed access
PDF file
YOYoshihiko Ooka
Yoshihiko Ooka
KMKanda Miho
Kanda Miho
OSObi Shuntaro
Obi Shuntaro
MNMasato Nakamura
Masato Nakamura
SOSadahisa Ogasawara
Sadahisa Ogasawara
MOMasao Omata
Masao Omata

18 December 2013 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
TMTenyu Motoyama
Tenyu Motoyama
SOSadahisa Ogasawara
Sadahisa Ogasawara
TCTetsuhiro Chiba
Tetsuhiro Chiba
THTakashi Higashide
Takashi Higashide
HYHajime Yokota
Hajime Yokota
OYOsamu Yokosuka
Osamu Yokosuka